Table 2.
Ongoing clinical trials with neoantigen cancer vaccines.
| Trial Number | Phase | Disease | Strategy | Sponsor/Investigator |
|---|---|---|---|---|
| NCT03639714 | 1/2 | NSCLC, CRC, Gastroesophageal cancer, Urothelial cancer | Adenovirus vector | Gritstone Oncology, Inc. |
| NCT03313778 | 1 | Solid tumors | mRNA | ModernaTX, Inc. |
| NCT03871205 | 1 | Lung cancer | DC | Shenzhen People’s Hospital/Lili Ren |
| NCT03674073 | 1 | HCC | DC | Chinese PLA General Hospital/Ping Liang |
| NCT02956551 | 1 | NSCLC | DC | Sichuan University/Zhen-YU Ding |
| NCT03532217 | 1 | Prostate cancer | DNA | Washington University School of Medicine/Russell Pachynski |
| NCT03122106 | 1 | Pancreatic cancer | DNA | Washington University School of Medicine/Gillanders et al. |
| NCT03199040 | 1 | Breast cancer | DNA | Washington University School of Medicine/William Gillanders |
| NCT04015700 | 1 | Glioblastoma | DNA | Washington University School of Medicine/Gavin Dunn |
| NCT03988283 | 1 | Pediatric recurrent brain tumor | DNA | Washington University School of Medicine/Karen M Gauvain |
| NCT03645148 | 1 | Pancreatic cancer | Peptide | Zhejiang Provincial People’s Hospital |
| NCT03558945 | 1 | Pancreatic cancer | Peptide | Changhai Hospital/Gang Jin |
| NCT03662815 | 1 | Advanced solid tumor | Peptide | Sir Run Run Shaw Hospital |
| NCT03715985 | 1 | Melanoma, NSCLC, Renal cell carcinoma | Peptide | Herlev Hospital/Inge Marie Svane |
| NCT02950766 | 1 | Renal cell carcinoma | Peptide | Patrick Ott |
| NCT03422094 | 1 | Glioblastoma | Peptide | Washington University School of Medicine/Gavin Dunn |
| NCT03361852 | 1 | Follicular lymphoma | Peptide | Dana-Farber Cancer Institute/Eric Jacobsen |
| NCT03929029 | 1 | Melanoma | Peptide | Dana-Farber Cancer Institute/Patrick A Ott |
| NCT03068832 | 1 | Pediatric brain tumor | Peptide | Washington University School of Medicine/Karen M Gauvain |
| NCT03606967 | 2 | Breast cancer | Peptide | National Cancer Institute/William Gillanders |
| NCT03219450 | 1 | Lymphocytic leukemia | Peptide | Dana-Farber Cancer Institute/Pavan Bachireddy |
NSCLC, non-small-cell lung carcinoma; CRC, colorectal cancer; mRNA, messenger ribonucleic acid; DC, dendritic cell; HCC, hepatocellular carcinoma; DNA, deoxyribonucleic acid.